SCHEMBL2762729

SCHEMBL2762729

O=C1CCCN1C(c1ccc(F)cc1)C(O)c1cccc2cccnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 1/20 0.44
FABP1 P07148 1/20 0.38
RCE1 Q9Y256 1/20 0.37
MAPT P10636 3/20 0.36
MAPK1 P28482 1/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
OPRM1 P35372 2/20 0.35
OPRD1 P41143 2/20 0.35
OPRK1 P41145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762827 0.83 PTGER3 (0.39) MAPTMEN1KMT2AKDM4ELMNA
SCHEMBL13036261 0.80 SSTR5 (0.38) P4HBFABP1MAPTMAPK1MEN1
SCHEMBL13036260 0.80 SSTR5 (0.38) P4HBFABP1MAPTMAPK1MEN1
SCHEMBL13084637 0.80 P4HB (0.37) P4HBFABP1RCE1MAPTMAPK1
SCHEMBL13036353 0.80 SSTR5 (0.38) P4HBFABP1MAPTMAPK1MEN1
SCHEMBL13036352 0.80 SSTR5 (0.38) P4HBFABP1MAPTMAPK1MEN1
SCHEMBL13084636 0.78 SSTR5 (0.38) P4HBFABP1MAPTMAPK1MEN1
SCHEMBL13036149 0.78 SSTR5 (0.38) P4HBFABP1MAPTMAPK1MEN1
SCHEMBL13036143 0.78 SSTR5 (0.38) P4HBFABP1MAPTMAPK1MEN1
SCHEMBL13036164 0.78 FABP1 (0.36) P4HBFABP1RCE1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825264-B2 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them SANOFI-AVENTIS (FR) 2010-11-02 US disclosed
EP-1899320-B1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KV1 .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI AVENTIS (FR) 2010-10-20 EP disclosed
US-20080188520-A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them SANOFI-AVENTIS (FR) 2008-08-07 US disclosed
EP-1899320-A1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Sanofi-Aventis (FR) 2008-03-19 EP disclosed
WO-2006136305-A1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI-AVENTIS (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188520-A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them KCNH1, MLLT3, CYP1A2 P4HB 1215/4885FABP1 4062/4885RCE1 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.